Abstract
Novel phenomena, such as constitutive activity and inverse agonism, have led to a ligand (re)classification along an agonists-neutral antagonist-inverse agonist continuum. This review focuses on adenosine A1 receptor ligands and their intrinsic activity (α). The intrinsic activity of a ligand depends both on the chemical characteristics of the compound itself and on the experimental conditions in which it is assayed. Consequently, due to this tissue-dependency determination of a ligands intrinsic activity is not always easily performed. Meanwhile, this feature may also be used in a profitable manner, namely to separate desired and unwanted effects of the drug. Briefly, this review provides possible screening methods to distinguish the different classes of ligands. It also deals with the structural elements and functional groups in the adenosine A1 receptor ligands that determine their intrinsic activity.
Keywords: adenosine receptor, inverse agonism, a1 receptor, intrinsic activity, partial agonism
Current Pharmaceutical Design
Title: Intrinsic Activity at Adenosine A1 Receptors: Partial and Inverse Agonism
Volume: 8 Issue: 26
Author(s): Rianne A.F. de Ligt and Ad P. Ijzerman
Affiliation:
Keywords: adenosine receptor, inverse agonism, a1 receptor, intrinsic activity, partial agonism
Abstract: Novel phenomena, such as constitutive activity and inverse agonism, have led to a ligand (re)classification along an agonists-neutral antagonist-inverse agonist continuum. This review focuses on adenosine A1 receptor ligands and their intrinsic activity (α). The intrinsic activity of a ligand depends both on the chemical characteristics of the compound itself and on the experimental conditions in which it is assayed. Consequently, due to this tissue-dependency determination of a ligands intrinsic activity is not always easily performed. Meanwhile, this feature may also be used in a profitable manner, namely to separate desired and unwanted effects of the drug. Briefly, this review provides possible screening methods to distinguish the different classes of ligands. It also deals with the structural elements and functional groups in the adenosine A1 receptor ligands that determine their intrinsic activity.
Export Options
About this article
Cite this article as:
de Ligt A.F. Rianne and Ijzerman Ad P., Intrinsic Activity at Adenosine A1 Receptors: Partial and Inverse Agonism, Current Pharmaceutical Design 2002; 8 (26) . https://dx.doi.org/10.2174/1381612023392874
DOI https://dx.doi.org/10.2174/1381612023392874 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The 2010 Patent Landscape for Spleen Tyrosine Kinase Inhibitors+
Recent Patents on Inflammation & Allergy Drug Discovery Peripheral Mononuclear Cell Rejuvenation for Senescence Surveillance in Alzheimer Disease
Current Pharmaceutical Design Metabolic Features Across the Female Life Span in Women with PCOS
Current Pharmaceutical Design Non Steroidal Anti Inflammatory Drugs As Gatekeepers Of Colon Carcinoma Highlight New Scenarios Beyond Cyclooxygenases Inhibition
Current Cancer Drug Targets Assessment of New E2 Protein Domain Interaction with PKR Protein to Control IFN Signaling
Current Proteomics Role of Inflammatory Cytokines in the Conversion of Mild Cognitive Impairment to Dementia: A Prospective Study
Current Alzheimer Research Partners in Crime: NGF and BDNF in Visceral Dysfunction
Current Neuropharmacology Extra-Hematopoietic Effects of Erythropoietin
Cardiovascular & Hematological Disorders-Drug Targets Vitiligo and Allergic Complications from Orthopaedic Joint Implants: The Role of Benzoyl Peroxide
Recent Patents on Inflammation & Allergy Drug Discovery Inflammation as a Therapeutic Target in Acute Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Mouse Models of Primary Sjogren’s Syndrome
Current Pharmaceutical Design Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies
Current Molecular Medicine Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance
CNS & Neurological Disorders - Drug Targets Translation Controlled mRNAs: New Drug Targets in Infectious Diseases?
Infectious Disorders - Drug Targets Three Arachidonoylamide Derivatives Inhibit Pro-Inflammatory Genes Expression by Modulating NF-κB and AP1 Activities
Medicinal Chemistry History and Global Status of the New Coronavirus Covid-2019 and Aspects of Previous Infections of SARS-CoV and MERS-CoV: A Systematic Review
Coronaviruses Determination of Human Serum α1-Acid Glycoprotein and Albumin Binding of Various Marketed and Preclinical Kinase Inhibitors
Current Medicinal Chemistry Characterization of the Effect of a Novel γ-secretase Modulator on Aβ: A Clinically Translatable Model
Current Pharmaceutical Design Dysregulated Interleukin -33/ST2 Pathway Perpetuates Chronic Inflammation in Hashimoto’s Thyroiditis
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial A New Year of Excellence
Current Molecular Medicine